"Cancer"

On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.

Blood cancer is a very complicated disease and should be treated in a timely manner to improve your disease and health condition and to gradually relieve your symptoms.

Immunotherapy has been a very important treatment in recent years, with many patients in lung cancer, malignant melanoma and many other cancers experiencing dramatic improvements in prognosis with this cutting-edge therapy. In pancreatic cancer, however, progress in immunotherapy has been very slow and its effectiveness has been extremely limited.

The University of Washington Medical Center owns and manages CUMG and the Seattle Cancer Care Alliance, which is a joint venture between the University of Washington Medical Center, Fred Hutchinson Cancer Research Center and Seattle Children's Hospital.

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

The Moffitt Cancer Center & Research Institute is a non-profit cancer treatment and research centre established in 1981 by the Florida Legislature and opened on the campus of the University of South Florida in October 1986.

Oesophageal cancer is a disease that causes a series of symptoms in our body, and it can be said to be a disease that seriously affects our health.

Both laryngeal cancer and laryngitis are common diseases, but there are some differences between these two diseases. Therefore, it is necessary for us to learn more about the common knowledge of laryngeal cancer and laryngitis, which can help us to prevent and detect the diseases.

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

Japan's top-ranked cancer treatment hospital